Oramed Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ORMP.TA research report →
Price Chart
About the company
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes.
- CEO
- Nadav Kidron
- IPO
- 2017
- Employees
- 13
- HQ
- New York, NY, US
Get TickerSpark's AI analysis on ORMP.TA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $572.97M
- P/E
- 1.13
- Fwd P/E
- 610.22
- PEG
- 0.00
- P/S
- 0.00
- P/B
- 0.62
- EV/EBITDA
- 1.09
- Div Yield
- 5.22%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 72.96%
- ROIC
- -3.77%
Latest fiscal year · YoY change
- Revenue
- $2.00M+0.0%
- Gross Profit
- $13.00K+101.8%
- Op Income
- $-15,087,999
- Net Income
- $64.05M+436.0%
- EPS
- $1.53+418.8%
- OCF Growth
- -8.7%
- FCF Growth
- -8.6%
- 52W High
- $1498.00
- 52W Low
- $6.91
- 50D MA
- $1267.36
- 200D MA
- $421.82
- Beta
- 1.16
- RSI (14)
- 61
- Avg Volume
- 5.88K
No earnings-call transcripts are available for ORMP.TA yet.
- Free Float
- 77.2%
- Shares Outstanding
- 40.93M
- Float Shares
- 31.59M
Our ORMP.TA coverage
Recent articles, reports, and earnings notes.
No research on ORMP.TA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ORMP.TA report →